Medications for obesity management: Effectiveness and value.
作者信息
Atlas Steven J, Kim Kibum, Nhan Emily, Touchette Daniel R, Moradi Ashton, Agboola Foluso, Rind David M, Beaudoin Francesca L, Pearson Steven D
机构信息
Division of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago.
出版信息
J Manag Care Spec Pharm. 2023 May;29(5):569-575. doi: 10.18553/jmcp.2023.29.5.569.
Abstract
摘要
相似文献
1
Medications for obesity management: Effectiveness and value.
J Manag Care Spec Pharm. 2023 May;29(5):569-575. doi: 10.18553/jmcp.2023.29.5.569.
2
Medications for obesity.
Can Fam Physician. 2008 Jun;54(6):848-9; author reply 849-50.
3
Medications for weight reduction.
Med Clin North Am. 2011 Sep;95(5):989-1008. doi: 10.1016/j.mcna.2011.06.009.
4
Obesity research--limitations of methods, measurements, and medications.
JAMA. 2006 Feb 15;295(7):826-8. doi: 10.1001/jama.295.7.826.
5
Next generation of weight management medications: implications for diabetes and CVD risk.
Curr Cardiol Rep. 2015 May;17(5):35. doi: 10.1007/s11886-015-0590-z.
6
Past, Present, and Future of Pharmacologic Therapy in Obesity.
Prim Care. 2016 Mar;43(1):61-7, viii. doi: 10.1016/j.pop.2015.08.011. Epub 2016 Jan 12.
7
Obesity medications reduce total body weight by 3-9% compared with placebo, when combined with lifestyle changes.
Evid Based Nurs. 2015 Jan;18(1):29-30. doi: 10.1136/eb-2014-101785. Epub 2014 May 19.
8
Treatment of obesity: an update on anti-obesity medications.
Obes Rev. 2003 Feb;4(1):25-42. doi: 10.1046/j.1467-789x.2003.00083.x.
9
New medications and new ways to use them.
Obesity (Silver Spring). 2015 Apr;23 Suppl 1:S1-4. doi: 10.1002/oby.21091.
10
[Effectiveness and risks of medicamentous treatment of obesity].
Cas Lek Cesk. 2010;149(12):605.
引用本文的文献
1
Resistance Exercise in Treating Heart Failure with Preserved Ejection Fraction (HFpEF) and Obesity: Targeting Skeletal Muscle Abnormalities and Ectopic Adipose Depots.
Physiologia. 2025 Mar;5(1). doi: 10.3390/physiologia5010010. Epub 2025 Feb 27.
2
Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society.
Obes Pillars. 2025 Jun 3;15:100181. doi: 10.1016/j.obpill.2025.100181. eCollection 2025 Sep.
3
Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society.
Am J Lifestyle Med. 2025 May 30:15598276251344827. doi: 10.1177/15598276251344827.
4
Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society.
Obesity (Silver Spring). 2025 May 30. doi: 10.1002/oby.24336.
5
Older Adults' Views on Insurance Coverage for Weight Management Medications.
JAMA Netw Open. 2025 Mar 3;8(3):e252008. doi: 10.1001/jamanetworkopen.2025.2008.
6
Factors Associated With Semaglutide Initiation Among Adults With Obesity.
JAMA Netw Open. 2025 Jan 2;8(1):e2455222. doi: 10.1001/jamanetworkopen.2024.55222.
7
A cost comparison of GLP-1 receptor agonists and bariatric surgery: what is the break even point?
Surg Endosc. 2024 Nov;38(11):6560-6565. doi: 10.1007/s00464-024-11191-1. Epub 2024 Sep 16.
8
Unraveling the Variability of Human Satiation: Implications for Precision Obesity Management.
Res Sq. 2024 May 23:rs.3.rs-4402499. doi: 10.21203/rs.3.rs-4402499/v1.
本文引用的文献
1
Association of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity.
JAMA. 2022 Jun 28;327(24):2423-2433. doi: 10.1001/jama.2022.9009.
2
Effectiveness of weight management interventions for adults delivered in primary care: systematic review and meta-analysis of randomised controlled trials.
BMJ. 2022 May 30;377:e069719. doi: 10.1136/bmj-2021-069719.
3
Reassessing Human Adipose Tissue.
N Engl J Med. 2022 Feb 24;386(8):768-779. doi: 10.1056/NEJMra2032804.
4
Patient-Centered Care for Obesity: How Health Care Providers Can Treat Obesity While Actively Addressing Weight Stigma and Eating Disorder Risk.
J Acad Nutr Diet. 2022 Jun;122(6):1089-1098. doi: 10.1016/j.jand.2022.01.004. Epub 2022 Jan 13.
5
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
JAMA. 2022 Jan 11;327(2):138-150. doi: 10.1001/jama.2021.23619.
6
Weight Discrimination Experienced Prior to Enrolling in a Behavioral Obesity Intervention is Associated with Treatment Response Among Black and White Adults in the Southeastern U.S.
Int J Behav Med. 2022 Apr;29(2):152-159. doi: 10.1007/s12529-021-10009-x. Epub 2021 Aug 2.
7
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Lancet. 2021 Mar 13;397(10278):971-984. doi: 10.1016/S0140-6736(21)00213-0. Epub 2021 Mar 2.
8
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
JAMA. 2021 Apr 13;325(14):1403-1413. doi: 10.1001/jama.2021.1831.
9
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10.
10
Direct medical costs of obesity in the United States and the most populous states.
J Manag Care Spec Pharm. 2021 Mar;27(3):354-366. doi: 10.18553/jmcp.2021.20410. Epub 2021 Jan 20.
Zotero 插件